Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review
Diseases,
Год журнала:
2025,
Номер
13(5), С. 129 - 129
Опубликована: Апрель 22, 2025
Obesity
is
a
growing
global
health
challenge,
necessitating
effective
treatment
options
beyond
lifestyle
interventions.
This
narrative
review
explores
established
and
emerging
pharmacotherapies
for
weight
management,
including
parenteral
agents
like
Liraglutide,
Semaglutide,
Setmelanotide,
Tirzepatide,
as
well
peroral
medications
such
Phentermine,
Phentermine/Topiramate,
Bupropion/Naltrexone,
Orlistat,
Metformin.
Newer
treatments
Cagrilintide
Bimagrumab
show
promise
enhancing
loss
outcomes.
Parenteral
GLP-1
receptor
agonists
demonstrate
superior
efficacy
compared
to
traditional
medications,
with
gastrointestinal
side
effects
being
the
most
common.
Artificial
intelligence
presents
intriguing
opportunities
enhance
strategies;
however,
its
integration
into
clinical
practice
remains
investigational
requires
rigorous
validation.
While
current
anti-obesity
deliver
significant
benefits,
future
research
must
determine
efficacy,
safety,
cost-effectiveness
of
AI-driven
approaches.
includes
exploring
how
AI
can
complement
combination
therapies
tailor
personalized
interventions,
thereby
grounding
potential
benefits
in
robust
evidence.
Future
directions
will
focus
on
integrating
trials
refine
personalize
obesity
management
strategies.
Язык: Английский
Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics
Journal of Nanobiotechnology,
Год журнала:
2025,
Номер
23(1)
Опубликована: Май 7, 2025
Obesity
is
a
major
global
health
challenge,
contributing
to
metabolic
disorders
such
as
type
2
diabetes,
cardiovascular
diseases,
and
hypertension.
The
increasing
prevalence
of
obesity,
driven
by
sedentary
lifestyles,
poor
dietary
habits,
genetic
predisposition,
underscores
the
urgent
need
for
effective
therapeutic
strategies.
Conventional
pharmacological
treatments,
including
appetite
suppressants
modulators,
often
fail
provide
sustainable
weight
loss
due
side
effects,
adherence,
limited
long-term
efficacy.
As
result,
natural
bioactive
compounds
have
gained
attention
their
anti-obesity
potential.
However,
clinical
application
hindered
bioavailability,
rapid
metabolism,
inefficient
delivery.
Lipid-based
nano-carriers,
liposomes,
solid
lipid
nanoparticles,
nanostructured
carriers,
offer
promising
solution
enhancing
solubility,
stability,
targeted
delivery
these
compounds.
These
advanced
systems
improve
retention,
enable
controlled
release,
enhance
action
on
adipose
tissue
pathways.
Additionally,
functionalized
stimulus-responsive
nanocarriers
present
innovative
approaches
precision
obesity
treatment.
Despite
advancements,
challenges
remain
in
large-scale
production,
regulatory
approval,
safety.
Overcoming
barriers
critical
ensuring
successful
translation
nano-formulated
therapies.
This
review
explores
potential
lipid-based
nano-carriers
optimizing
efficacy
highlights
role
advancing
next-generation
management
Язык: Английский
GLP-1 RA Prescribing Errors in a Multidisciplinary Digital Weight-Loss Service: A Retrospective Quantitative Analysis
Healthcare,
Год журнала:
2024,
Номер
12(20), С. 2093 - 2093
Опубликована: Окт. 21, 2024
Digital
weight
loss
services
(DWLSs)
that
use
Glucagon-like
peptide-1
receptor
agonists
(GLP-1
RAs)
have
demonstrated
potential
in
contributing
to
a
shift
global
obesity
rates.
However,
reasonable
concerns
been
raised
about
the
prescribing
safety
of
these
services.
Prior
this
study,
electronic
had
only
investigated
hospital
settings
and
community
clinics.
Язык: Английский
Navigating coverage: A qualitative study exploring the perceived impact of an insurance company policy to discontinue coverage of antiobesity medication
Obesity Pillars,
Год журнала:
2024,
Номер
11, С. 100120 - 100120
Опубликована: Июль 22, 2024
Obesity
rates
continue
to
rise
in
the
United
States.
Treatment
includes
modification
of
diet,
exercise,
behavioral
and
medical
consideration
including
anti-obesity
medications.
However,
multiple
highly
effective
medications
are
expensive
with
that
we
see
insurers
opting
out
coverage
these
This
has
led
patients
having
abruptly
stop
treatment
The
purpose
this
study
is
explore
impact
non-medical
discontinuance
obesity
medication
among
weight
management
programs.
Язык: Английский
Ozempic (Glucagon-like peptide 1 receptor agonist) in social media posts: Unveiling user perspectives through Reddit topic modeling
Emerging Trends in Drugs Addictions and Health,
Год журнала:
2024,
Номер
4, С. 100157 - 100157
Опубликована: Сен. 3, 2024
Semaglutide,
a
Glucagon-like
peptide
1
(GLP-1)
receptor
agonist
marketed
under
the
brand
name
Ozempic,
is
originally
prescribed
for
diabetes
treatment
and
obesity
management.
However,
healthy
individuals
without
medical
cause
use
Ozempic
supervision
to
improve
their
physical
appearance
-
trend
that
has
proliferated
through
social
media,
news
coverage,
relevant
celebrity
endorsements.
Thus,
exploring
media
posts
can
provide
insight
into
understanding
individuals'
experiences,
beliefs,
motivation,
as
well
misconceptions
about
Ozempic.
To
do
so,
this
study
utilizes
BERTopic,
natural
language
processing
approach
topic
modeling,
analyze
46,491
Reddit
from
three
subreddits
(r/ozempic,
r/ozempicforweightloss,
r/semaglutide)
dated
between
April
2019
December
2023.
The
analysis
revealed
various
discussion
topics,
including
using
weight
loss,
dosaging,
insurance
denial
due
lack
of
diagnosis,
loss
tracking,
side
effect
Overall,
overarching
theme
centered
on
off-label
its
GLP-1
counterparts
purposes.
Moreover,
awareness
health
hazards
associated
with
unsupervised
an
image
enhancer
not
frequently
appear
in
discussions.
These
findings,
supported
by
dynamic
modeling
analysis,
offer
ecological
insights
experiences
opinions
community
members
Ozempic-related
subreddits,
reinforcing
growing
evidence
drug's
increasing
popularity
management
role
played
media.
also
shows
how
information
campaigns
risks
may
help
counterbalance
risk
detected
Язык: Английский